<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN (RSV-IVIG)</span><br/>(res-pir'a-tory sin-cy'ti-al)<br/><span class="topboxtradename">RespiGam<br/></span><b>Classifications:</b> <span class="classification"> biologic response modifier</span>; <span class="classification">immunoglobulin</span><br/><b>Prototype: </b>Immune Globulin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2500 mg/50 mL vial</p>
<h1><a name="action">Actions</a></h1>
<p>Contains IgG immune globulin antibodies from human plasma.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The preparation contains large amounts of RSV-neutralizing antibodies. Recipients should be high-risk premature infants and
         children.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prevention of serious lower respiratory tract infection caused by RSV in children 
      </p><h1><a name="contrain">Contraindications</a></h1>
<p>Previous severe reaction to RespiGam or other human immunoglobulin preparation, selective IgA deficiency, congenital heart
         disease, hepatic disease, pregnancy (category C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Immunodeficiency, AIDS, CHF, renal failure.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">RSV</span><br/><span class="rdage">Child/</span><span class="rdage">Infant/</span><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 750 mg/kg infused at 1.5 mL/kg/h for first 15 min, then 3 mL/kg/h for next 15 min, then 6 mL/kg/h  for rest of infusion, may repeat monthly as needed<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Do not shake vial; infuse vial contents undiluted through a separate IV line if possible; if "piggyback" must be used,
                  see manufacturer's directions. <u><small>DO NOT EXCEED IV INFUSION RATES</small></u> given in Route &amp; Dosage table! Use a constant infusion pump.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive or Y-site:</span> Do not mix with other drugs. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store vials at 2°8° C (35°46° F). Begin infusion within 6 h after vial is entered and complete
            within 12 h.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fever, pyrexia, fluid overload. <span class="typehead">CV:</span> Tachycardia, hypertension. <span class="typehead">GI:</span> Vomiting, diarrhea, gastroenteritis. <span class="typehead">Respiratory:</span> Respiratory distress, wheezing, rales, hypoxia, hypoxemia, tachypnea. <span class="typehead">Skin:</span> Injection site inflammation. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May interfere with immune response to <span class="classification">live virus vaccines</span> (mumps, rubella, measles), may need to repeat vaccine if given within 10 mo of <b>RespiGam.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Half-Life:</span> 2228 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor closely during and after each IV rate change.</li>
<li>Assess vital signs and respiratory status prior to infusion, during and after each rate change, and at 30-min intervals until
            30 min after infusion is completed, and periodically thereafter for 24 h.
         </li>
<li>Slow infusion immediately if S&amp;S of fluid overload appear and report to physician.</li>
<li>Lab tests: Monitor routine blood chemistry, serum electrolytes, blood gases, osmolality.</li>
<li>Monitor for aseptic meningitis syndrome, which may begin up to 2 d after infusion.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware of the possibility of aseptic meningitis syndrome; learn S&amp;S to report (headache, drowsiness, fever, photophobia,
            painful eye movements, muscle rigidity, nausea, vomiting).
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>